• Something wrong with this record ?

Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable

S. Georgiadis, LM. Ørnbjerg, B. Michelsen, TK. Kvien, D. Di Giuseppe, JK. Wallman, J. Závada, SA. Provan, EK. Kristianslund, AM. Rodrigues, MJ. Santos, Ž. Rotar, KP. Pirkmajer, D. Nordström, GJ. Macfarlane, GT. Jones, I. van der Horst-Bruinsma,...

. 2024 ; 51 (7) : 673-677. [pub] 20240701

Language English Country Canada

Document type Journal Article

OBJECTIVE: Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP) is recommended over ASDAS based on erythrocyte sedimentation rate (ASDAS-ESR) to assess disease activity in axial spondyloarthritis (axSpA). Although ASDAS-CRP and ASDAS-ESR are not interchangeable, the same disease activity cut-offs are used for both. We aimed to estimate optimal ASDAS-ESR values corresponding to the established ASDAS-CRP cut-offs (1.3, 2.1, and 3.5) and investigate the potential improvement of level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states when applying these estimated cut-offs. METHODS: We used data from patients with axSpA from 9 European registries initiating a tumor necrosis factor inhibitor. ASDAS-ESR cut-offs were estimated using the Youden index. The level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states was compared against each other. RESULTS: In 3664 patients, mean ASDAS-CRP was higher than ASDAS-ESR at both baseline (3.6 and 3.4, respectively) and aggregated follow-up at 6, 12, or 24 months (1.9 and 1.8, respectively). The estimated ASDAS-ESR values corresponding to the established ASDAS-CRP cut-offs were 1.4, 1.9, and 3.3. By applying these cut-offs, the proportion of discordance between disease activity states according to ASDAS-ESR and ASDAS-CRP decreased from 22.93% to 19.81% in baseline data but increased from 27.17% to 28.94% in follow-up data. CONCLUSION: We estimated the optimal ASDAS-ESR values corresponding to the established ASDAS-CRP cut-off values. However, applying the estimated cut-offs did not increase the level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states to a relevant degree. Our findings did not provide evidence to reject the established cut-off values for ASDAS-ESR.

1 van der Horst Bruinsma MD PhD Rheumatology Radboud University Medical Center Nijmegen the Netherlands

A M Rodrigues MD PhD EpiDoC Unit CEDOC Nova Medical School and Rheumatology Unit Hospital dos Lusíadas Lisbon Portugal

B Michelsen MD PhD Center for Treatment of Rheumatic and Musculoskeletal Diseases Center for Rheumatology and Spine Diseases Centre for Head and Orthopaedics Copenhagen University Hospital Rigshospitalet Glostrup Denmark

D Di Giuseppe PhD Clinical Epidemiology Division Department of Medicine Solna Karolinska Institutet Stockholm Sweden

D Nordström MD PhD Departments of Medicine and Rheumatology Helsinki University Hospital Helsinki Finland

G J Macfarlane MD PhD G T Jones PhD Aberdeen Centre for Arthritis and Musculoskeletal Health University of Aberdeen Aberdeen UK

J K Wallman MD PhD Department of Clinical Sciences Lund Rheumatology Skåne University Hospital Lund University Lund Sweden

J Závada MD PhD Institute of Rheumatology Prague Czech Republic and Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

M J Santos MD PhD Department of Rheumatology Hospital Garcia de Orta Almada and Instituto Medicina Molecular Faculdade de Medicina da Universidade de Lisboa Centro Académico de Medicina de Lisboa Lisbon Portugal

M Østergaard MD PhD DMSc M L Hetland MD PhD DMSc Copenhagen Center for Arthritis Research Center for Rheumatology and Spine Diseases Centre for Head and Orthopaedics Rigshospitalet Glostrup and Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

P Hellamand MD Department of Rheumatology and Clinical Immunology Amsterdam University Medical Center Amsterdam Netherlands and Amsterdam Rheumatology Immunology Center Reade and Amsterdam UMC Amsterdam the Netherlands

S A Provan MD PhD Center for Treatment of Rheumatic and Musculoskeletal Diseases Diakonhjemmet Hospital Oslo and Public Health Section Inland Norway University of Applied Sciences Elverum Norway

S Georgiadis PhD L M Ørnbjerg MD PhD Copenhagen Center for Arthritis Research Center for Rheumatology and Spine Diseases Centre for Head and Orthopaedics Rigshospitalet Glostrup Denmark

T K Kvien MD PhD E K Kristianslund MD PhD Center for Treatment of Rheumatic and Musculoskeletal Diseases Diakonhjemmet Hospital Oslo Norway

Ž Rotar MD PhD K Perdan Pirkmajer MD Department of Rheumatology University Medical Centre Ljubljana and Faculty of Medicine University of Ljubljana Ljubljana Slovenia

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019928
003      
CZ-PrNML
005      
20241024110843.0
007      
ta
008      
241015s2024 xxc f 000 0|eng||
009      
AR
024    7_
$a 10.3899/jrheum.2023-1217 $2 doi
035    __
$a (PubMed)38621792
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxc
100    1_
$a Georgiadis, Stylianos $u S. Georgiadis, PhD, L.M. Ørnbjerg, MD, PhD, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark; stylianos.georgiadis@regionh.dk $1 https://orcid.org/0000000334859457
245    10
$a Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable / $c S. Georgiadis, LM. Ørnbjerg, B. Michelsen, TK. Kvien, D. Di Giuseppe, JK. Wallman, J. Závada, SA. Provan, EK. Kristianslund, AM. Rodrigues, MJ. Santos, Ž. Rotar, KP. Pirkmajer, D. Nordström, GJ. Macfarlane, GT. Jones, I. van der Horst-Bruinsma, P. Hellamand, M. Østergaard, ML. Hetland
520    9_
$a OBJECTIVE: Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP) is recommended over ASDAS based on erythrocyte sedimentation rate (ASDAS-ESR) to assess disease activity in axial spondyloarthritis (axSpA). Although ASDAS-CRP and ASDAS-ESR are not interchangeable, the same disease activity cut-offs are used for both. We aimed to estimate optimal ASDAS-ESR values corresponding to the established ASDAS-CRP cut-offs (1.3, 2.1, and 3.5) and investigate the potential improvement of level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states when applying these estimated cut-offs. METHODS: We used data from patients with axSpA from 9 European registries initiating a tumor necrosis factor inhibitor. ASDAS-ESR cut-offs were estimated using the Youden index. The level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states was compared against each other. RESULTS: In 3664 patients, mean ASDAS-CRP was higher than ASDAS-ESR at both baseline (3.6 and 3.4, respectively) and aggregated follow-up at 6, 12, or 24 months (1.9 and 1.8, respectively). The estimated ASDAS-ESR values corresponding to the established ASDAS-CRP cut-offs were 1.4, 1.9, and 3.3. By applying these cut-offs, the proportion of discordance between disease activity states according to ASDAS-ESR and ASDAS-CRP decreased from 22.93% to 19.81% in baseline data but increased from 27.17% to 28.94% in follow-up data. CONCLUSION: We estimated the optimal ASDAS-ESR values corresponding to the established ASDAS-CRP cut-off values. However, applying the estimated cut-offs did not increase the level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states to a relevant degree. Our findings did not provide evidence to reject the established cut-off values for ASDAS-ESR.
650    _2
$a lidé $7 D006801
650    12
$a C-reaktivní protein $x analýza $7 D002097
650    12
$a krevní sedimentace $7 D001799
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a ankylózující spondylitida $x krev $x diagnóza $7 D013167
650    12
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a dospělí $7 D000328
650    _2
$a lidé středního věku $7 D008875
650    12
$a axiální spondyloartritida $x krev $x diagnóza $7 D000089183
650    _2
$a registrace $7 D012042
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ørnbjerg, Lykke Midtbøll $u S. Georgiadis, PhD, L.M. Ørnbjerg, MD, PhD, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark $1 https://orcid.org/0000000278326831
700    1_
$a Michelsen, Brigitte $u B. Michelsen, MD, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, and Research Unit, Sørlandet Hospital, Kristiansand, Norway, and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark $1 https://orcid.org/0000000301032840
700    1_
$a Kvien, Tore K $u T.K. Kvien, MD, PhD, E.K. Kristianslund, MD, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway $1 https://orcid.org/0000000284413093
700    1_
$a Di Giuseppe, Daniela $u D. Di Giuseppe, PhD, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000338178288
700    1_
$a Wallman, Johan K $u J.K. Wallman, MD, PhD, Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden $1 https://orcid.org/0000000249152924
700    1_
$a Závada, Jakub $u J. Závada, MD, PhD, Institute of Rheumatology, Prague, Czech Republic and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000298026545 $7 xx0160054
700    1_
$a Provan, Sella A $u S.A. Provan, MD, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, and Public Health Section, Inland Norway University of Applied Sciences, Elverum, Norway $1 https://orcid.org/000000015442902X
700    1_
$a Kristianslund, Eirik Klami $u T.K. Kvien, MD, PhD, E.K. Kristianslund, MD, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway $1 https://orcid.org/0000000249633285
700    1_
$a Rodrigues, Ana Maria $u A.M. Rodrigues, MD, PhD, EpiDoC Unit, CEDOC, Nova Medical School, and Rheumatology Unit, Hospital dos Lusíadas, Lisbon, Portugal $1 https://orcid.org/0000000320468017
700    1_
$a Santos, Maria José $u M.J. Santos, MD, PhD, Department of Rheumatology, Hospital Garcia de Orta, Almada, and Instituto Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal $1 https://orcid.org/0000000279461365
700    1_
$a Rotar, Žiga $u Ž. Rotar, MD, PhD, K. Perdan Pirkmajer, MD, Department of Rheumatology, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia $1 https://orcid.org/0000000293239189
700    1_
$a Pirkmajer, Katja Perdan $u Ž. Rotar, MD, PhD, K. Perdan Pirkmajer, MD, Department of Rheumatology, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia $1 https://orcid.org/0000000177784016
700    1_
$a Nordström, Dan $u D. Nordström, MD, PhD, Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland $1 https://orcid.org/0000000236616072
700    1_
$a Macfarlane, Gary J $u G.J. Macfarlane, MD, PhD, G.T. Jones, PhD, Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK $1 https://orcid.org/0000000323223314
700    1_
$a Jones, Gareth T $u G.J. Macfarlane, MD, PhD, G.T. Jones, PhD, Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK $1 https://orcid.org/0000000300167591
700    1_
$a van der Horst-Bruinsma, Irene $u I. van der Horst-Bruinsma, MD, PhD, Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands $1 https://orcid.org/0000000280869915
700    1_
$a Hellamand, Pasoon $u P. Hellamand, MD, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam, Netherlands and Amsterdam Rheumatology Immunology Center, Reade, and Amsterdam UMC, Amsterdam, the Netherlands $1 https://orcid.org/0000000222513435
700    1_
$a Østergaard, Mikkel $u M. Østergaard, MD, PhD, DMSc, M.L. Hetland, MD, PhD, DMSc, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/000000033690467X
700    1_
$a Hetland, Merete Lund $u M. Østergaard, MD, PhD, DMSc, M.L. Hetland, MD, PhD, DMSc, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000342296818
773    0_
$w MED00002935 $t The Journal of rheumatology $x 1499-2752 $g Roč. 51, č. 7 (2024), s. 673-677
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38621792 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110837 $b ABA008
999    __
$a ok $b bmc $g 2202257 $s 1231901
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 51 $c 7 $d 673-677 $e 20240701 $i 1499-2752 $m The Journal of rheumatology $n J Rheumatol $x MED00002935
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...